Palisade Bio (PALI) Competitors $0.66 -0.03 (-4.78%) As of 09:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. ME, AYTU, LIPO, ATHA, NEUP, NERV, AIMD, BCTX, ALLR, and INABShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include 23andMe (ME), Aytu BioPharma (AYTU), Lipella Pharmaceuticals (LIPO), Athira Pharma (ATHA), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Minerva Neurosciences (NERV), Ainos (AIMD), BriaCell Therapeutics (BCTX), Allarity Therapeutics (ALLR), and IN8bio (INAB). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors 23andMe Aytu BioPharma Lipella Pharmaceuticals Athira Pharma Neuphoria Therapeutics Inc. - Common Stock Minerva Neurosciences Ainos BriaCell Therapeutics Allarity Therapeutics IN8bio Palisade Bio (NASDAQ:PALI) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership. Do analysts recommend PALI or ME? Palisade Bio presently has a consensus price target of $12.00, suggesting a potential upside of 1,726.48%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Palisade Bio is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.0023andMe 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the MarketBeat Community favor PALI or ME? 23andMe received 1 more outperform votes than Palisade Bio when rated by MarketBeat users. However, 52.38% of users gave Palisade Bio an outperform vote while only 46.15% of users gave 23andMe an outperform vote. CompanyUnderperformOutperformPalisade BioOutperform Votes1152.38% Underperform Votes1047.62% 23andMeOutperform Votes1246.15% Underperform Votes1453.85% Which has more volatility & risk, PALI or ME? Palisade Bio has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Does the media prefer PALI or ME? In the previous week, 23andMe had 16 more articles in the media than Palisade Bio. MarketBeat recorded 18 mentions for 23andMe and 2 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.43 beat 23andMe's score of -0.09 indicating that Palisade Bio is being referred to more favorably in the media. Company Overall Sentiment Palisade Bio Neutral 23andMe Neutral Which has higher valuation and earnings, PALI or ME? Palisade Bio has higher earnings, but lower revenue than 23andMe. Palisade Bio is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K12.60-$12.30M-$6.80-0.1023andMe$208.78M0.06-$666.70M-$15.45-0.03 Do insiders & institutionals have more ownership in PALI or ME? 11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 3.3% of Palisade Bio shares are owned by insiders. Comparatively, 26.3% of 23andMe shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is PALI or ME more profitable? Palisade Bio has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Palisade Bio's return on equity of -148.51% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -148.51% -115.16% 23andMe -183.39%-170.07%-62.13% SummaryPalisade Bio beats 23andMe on 11 of the 18 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.15M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.0532.9027.1419.96Price / Sales12.60466.20414.30157.63Price / CashN/A168.6838.2534.64Price / Book0.043.427.074.69Net Income-$12.30M-$72.35M$3.23B$248.14M7 Day Performance-5.70%2.59%0.71%0.91%1 Month Performance-10.01%20.47%9.65%5.71%1 Year Performance-85.53%-17.11%32.07%14.71% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.3924 of 5 stars$0.66-4.8%$12.00+1,726.5%-84.5%$3.15M$250K-0.0510Short Interest ↑Gap UpME23andMeN/A$0.50-35.3%N/A-94.0%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeAYTUAytu BioPharma1.491 of 5 stars$2.11+5.5%N/A-34.3%$13.02M$81.66M-1.46160Short Interest ↓Gap UpHigh Trading VolumeLIPOLipella Pharmaceuticals2.2713 of 5 stars$2.91-2.7%N/A-47.9%$13.00M$536.36K-0.684Positive NewsATHAAthira Pharma2.9086 of 5 stars$0.33-8.1%$13.83+4,079.3%-88.1%$12.92MN/A-0.1240Positive NewsGap DownNEUPNeuphoria Therapeutics Inc. - Common Stock2.0226 of 5 stars$6.82-0.7%$21.00+207.9%N/A$12.92M$15.66M0.00N/AGap UpNERVMinerva Neurosciences3.4414 of 5 stars$1.84flat$5.00+171.7%-45.1%$12.87MN/A-4.189Gap UpAIMDAinos1.3874 of 5 stars$0.62-6.2%N/A-35.5%$12.84M$106.21K-0.4840Positive NewsGap DownBCTXBriaCell Therapeutics1.7232 of 5 stars$3.48+1.2%$32.00+819.5%-82.0%$12.76MN/A-0.268Short Interest ↑Gap DownALLRAllarity Therapeutics0.5526 of 5 stars$0.88+4.2%N/A-94.5%$12.76MN/A0.0010News CoverageINABIN8bio3.5848 of 5 stars$3.08-26.1%$180.00+5,744.2%-94.6%$12.61MN/A-4.1120Stock SplitShort Interest ↓High Trading Volume Related Companies and Tools Related Companies ME Alternatives AYTU Alternatives LIPO Alternatives ATHA Alternatives NEUP Alternatives NERV Alternatives AIMD Alternatives BCTX Alternatives ALLR Alternatives INAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PALI Stock Free PALI Stock Alerts